Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Adam BlaisdellYan ZhouMichael G KattahSusan J FisherUma MahadevanPublished in: Inflammatory bowel diseases (2022)
This study revealed a previously unrecognized role for α4β7 and MAdCAM-1 in human placentation. More clinical and histological data from Vedolizumab-treated pregnant patients will be necessary to determine whether this medication poses any risk to the mother and fetus.
Keyphrases
- endothelial cells
- end stage renal disease
- newly diagnosed
- induced pluripotent stem cells
- chronic kidney disease
- healthcare
- ulcerative colitis
- patients with inflammatory bowel disease
- prognostic factors
- big data
- staphylococcus aureus
- machine learning
- electronic health record
- escherichia coli
- patient reported outcomes
- cystic fibrosis
- patient reported
- artificial intelligence